Keywords: gsk, licenses, galapagos, anti-infectives, uk, drug, major

GSK licenses Galapagos' anti-infectives

Article | 17 December 2007

Print This

UK drug major GlaxoSmithKline has licensed product candidates from Galapagos NV directed against up to six anti-infective targets. As part ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in